Eplerenone in the Treatment of Polypoidal Choroidal Vasculopathy

Overactivation of mineralocorticoid receptor pathways has been implicated in the pathophysiology of central serous chorioretinopathy (CSCR). Recently, mineralocorticoid receptor antagonists such as eplerenone have demonstrated success in treating subretinal fluid in CSCR. This case demonstrates a patient who was initially presumed to have subretinal fluid secondary to CSCR and was started on a trial of oral eplerenone. It quickly became evident that her subretinal fluid was secondary to a peripapillary polypoidal choroidal vasculopathy network, but she demonstrated a significant improvement with oral eplerenone. To the authors'' knowledge, this is the first case of eplerenone use to treat polypoidal choroidal vasculopathy.Key Words: Eplerenone, Mineralocorticoid antagonist, Polypoidal choroidal vasculopathy